Should I invest in penny stock Sareum (LSE:SAR)?

Sareum Holdings is a penny stock generating interest as its drug development work makes waves in the Covid-19 space. Is it a good investment?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Drug development company Sareum Holdings (LSE:SAR) specialises in developing therapeutics for cancer and autoimmune diseases such as arthritis and irritable bowel disease (IBD). Last year, heightened interest in biopharma stocks led the Sareum share price to rocket over 572%. And this year, its ascent has continued, with its share price hitting a high of 9.5p in June. This momentum has brought the penny stock to the attention of many UK growth investors.

What does Sareum do?

Sareum is a small molecule drug company developing targeted therapeutics. However, it doesn’t do the initial research. Instead, the team learns from others in the game using a low-cost research outsource model.

The team looks for drug candidates they believe will go all the way through clinical trials. Sareum then further designs the chosen molecules in-house and commissions lab work to proceed.

For instance, some existing autoimmune treatments treat the disease but have terrible side effects like thrombosis or severe infection. The Sareum Holdings team believes the TYK2/JAK1 inhibitors within these treatments can be enhanced to generate quality drugs that work with the immune system, devoid of the terrible side effects.

It’s already taking these through preclinical trials to test for the optimum dose and evaluate toxicology levels.

The company does not plan to commercialise drugs. Instead, it progresses to early clinical trials (phase 1 or 2) but will then licence to a partner.

For instance, Sareum licensed its CHK1 inhibitor SRA737 cancer treatment to Sierra Oncology. And its association with Sierra has lent considerable credibility to Sareum stock.

Furthermore, it has also been running a Covid-19 research programme. This is to see if its candidate molecule SDC-1801 can treat a cytokine storm in Covid-19 patients, along with protection against bacterial pneumonia. Meanwhile, SDC-1801 is being researched to treat psoriasis and rheumatoid arthritis.

Penny stocks can be a money pit

Today, Sareum is a penny stock with a £209m market cap. Its share price is up 1,160% from its 52-week low and down 34% from its 52-week high.

Sareum may well have further to climb. But penny stocks are notoriously risky investments.

In mid-June, the company raised £1.4m from the distribution of 30m additional shares. One high-net-worth individual bought the shares after already buying £900k worth of shares on 1 June.

This money is to be used to progress its TYK2/JAK1 programmes into clinical development. But it will also be used as working capital. The buyer also received a five-year warrant, which can be sold when the share price is above 7p for five consecutive days. That’s only 11% higher than it is today.

Furthermore, the company will need to raise additional funds in the coming weeks to undertake clinical trials for its autoimmune indications and a potential Covid-19 application.

Will this top biotech slide or soar?

Based in the UK, Sareum became the third-best-performing European biotech small-cap company last year. I think much of the success of the Sareum share price is due to the Covid-19-related hyping of biotech stocks.

Unfortunately, penny stocks are volatile, and I think this share price could just as easily slide as soar. I think Sareum does have some enticing reasons to be bullish, but it’s too risky for me. When investing in pharma stocks I prefer an established company like AstraZeneca.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: our 3 top income-focused stocks to buy before April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

Is this the best chance to buy cheap FTSE 100 shares in a generation?

I want to buy shares when they're cheap, and sell... never, just keep taking the dividends. And the FTSE 100…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Could NatWest shares be 2024’s number one buy for passive income?

For those of us looking to earn some long-term passive income, how does NatWest's 7% dividend yield sound? It sounds…

Read more »

Investing Articles

£12K in savings? Here’s how I could turn that into £13K annual passive income

This Fool explains how investing a lump sum can help her build a passive income stream to enjoy in her…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Here’s why Rolls-Royce shares are now set to fly over the £4 mark

Once again, Rolls-Royce shares are crushing the FTSE 100. Should I add to my holding of this stock at the…

Read more »

Investing Articles

1 under the radar FTSE 100 AI stock investors should consider buying

Our writer explains why this FTSE 100 pick could be a shrewd investment with its established experience of using AI…

Read more »

Investing Articles

Does the beaten-down Diageo share price make it a no-brainer buy?

Harvey Jones spent years waiting for the Diageo share price to look like good value, before finally buying it in…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

8%+ yields! Should I buy these FTSE 100 income shares this month?

Christopher Ruane weighs some pros and cons of two FTSE 100 shares, both of which have a dividend yield over…

Read more »